MIRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mirum Pharmaceuticals (MIRM) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company's strong revenue growth, promising pipeline, and positive analyst sentiment outweigh the risks of current negative free cash flow and declining net income. Given the upcoming pivotal clinical study results and the potential for significant long-term value, the stock presents a solid opportunity for long-term investment.
The stock shows bullish momentum with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.473. RSI is neutral at 52.583, indicating no overbought or oversold conditions. Key support and resistance levels are Pivot: 96.053, R1: 98.741, and S1: 93.365. The pre-market price of $96.36 is slightly above the pivot point, suggesting potential upward movement.
Analysts have consistently raised price targets, with the highest at $132, citing strong commercial momentum and potential for $4 billion peak sales from the pipeline.
Upcoming pivotal clinical study results over the next 18 months, including Phase 3 data in Q2 2026, could unlock significant value.
Livmarli sales increased 69% YoY, reflecting strong demand.
Management expects a return to positive cash flow by 2027, indicating long-term sustainability.
Negative free cash flow projected for 2026 due to increased R&D spending.
Declining net income (-75.91% YoY) and EPS (-77.55% YoY) in Q4
High implied volatility (83.
and IV percentile (94), suggesting elevated risk in the options market.
In Q4 2025, revenue increased by 49.81% YoY to $148.93 million, and gross margin improved to 81.02%. However, net income dropped by 75.91% YoY to -$5.73 million, and EPS fell by 77.55% YoY to -0.11. Despite these declines, the company generated positive free cash flow in 2025, indicating strong market demand.
Analysts maintain a positive outlook with multiple 'Buy' and 'Outperform' ratings. Price targets range from $115 to $132, with firms citing strong revenue growth, promising pipeline developments, and multiple catalysts in 2026 as reasons for optimism.
